AlphaCentric Advisors LLC Purchases New Shares in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

AlphaCentric Advisors LLC acquired a new position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 17,500 shares of the company’s stock, valued at approximately $329,000. AlphaCentric Advisors LLC owned 0.12% of Jasper Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Wolff Wiese Magana LLC acquired a new position in Jasper Therapeutics in the 3rd quarter worth about $59,000. Virtu Financial LLC acquired a new stake in Jasper Therapeutics in the 1st quarter valued at $306,000. Rhumbline Advisers acquired a new stake in Jasper Therapeutics in the 2nd quarter valued at $300,000. American Century Companies Inc. grew its stake in Jasper Therapeutics by 27.1% in the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after acquiring an additional 3,032 shares during the period. Finally, Concurrent Investment Advisors LLC purchased a new stake in Jasper Therapeutics in the 1st quarter worth $599,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on JSPR. JMP Securities reiterated a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. Evercore ISI reaffirmed an “outperform” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Monday, August 26th. HC Wainwright reissued a “buy” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Finally, Royal Bank of Canada reduced their target price on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a research report on Wednesday, August 14th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $74.86.

Jasper Therapeutics Price Performance

Shares of JSPR opened at $22.03 on Tuesday. Jasper Therapeutics, Inc. has a 12-month low of $4.00 and a 12-month high of $31.01. The firm has a 50-day moving average price of $19.71 and a 200 day moving average price of $20.86.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.12. On average, sell-side analysts anticipate that Jasper Therapeutics, Inc. will post -4.16 earnings per share for the current year.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.